Kingsview Wealth Management LLC Has $2.55 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Kingsview Wealth Management LLC reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 15.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 21,392 shares of the company’s stock after selling 3,908 shares during the quarter. Kingsview Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $2,547,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the 2nd quarter worth $25,000. Strategic Investment Solutions Inc. IL bought a new position in shares of Novo Nordisk A/S in the second quarter worth about $25,000. Gilliland Jeter Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the last quarter. Halpern Financial Inc. grew its holdings in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after buying an additional 113 shares during the last quarter. Finally, Abound Wealth Management increased its position in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $105.06 on Monday. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $471.46 billion, a P/E ratio of 34.00, a PEG ratio of 1.35 and a beta of 0.42. The company’s 50-day simple moving average is $115.48 and its 200 day simple moving average is $128.81.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on NVO shares. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.